Purple Biotech has entered a research collaboration with the Icahn School of Medicine at Mount Sinai.

紫色生物技术公司与西奈山伊坎医学院进行了研究合作。

The partnership aims to investigate the immunoregulatory effects of the company’s CAPTN-3 multi-specific engagers on NK and T cells within the tumour microenvironment (TME). The goal is to enhance tumour-specific immune responses against various cancers.

该伙伴关系旨在研究该公司的CAPTN-3多特异性参与者对肿瘤微环境（TME）内NK和T细胞的免疫调节作用。。

The collaboration involves experts from the Marc and Jennifer Lipschultz Precision Immunology Institute and The Tisch Cancer Institute at Mount Sinai.

这项合作涉及来自马克和詹妮弗·利普舒尔茨精密免疫学研究所以及西奈山蒂希癌症研究所的专家。

It is expected to provide deeper insights into the mechanisms of action of CAPTN-3, supporting its transition towards clinical trials. Multi-specific engagers have recently attracted increasing attention in oncology research, and this study will contribute to advancing CAPTN-3 development for future human trials..

预计它将为CAPTN-3的作用机制提供更深入的见解，支持其向临床试验的过渡。多特异性参与者最近在肿瘤学研究中引起了越来越多的关注，这项研究将有助于推动CAPTN-3在未来人体试验中的发展。。

Purple Biotech has entered a research collaboration with the Icahn School of Medicine at Mount Sinai.

紫色生物技术公司与西奈山伊坎医学院进行了研究合作。

The partnership aims to investigate the immunoregulatory effects of the company’s CAPTN-3 multi-specific engagers on NK and T cells within the tumour microenvironment (TME). The goal is to enhance tumour-specific immune responses against various cancers.

该伙伴关系旨在研究该公司的CAPTN-3多特异性参与者对肿瘤微环境（TME）内NK和T细胞的免疫调节作用。。

The collaboration involves experts from the Marc and Jennifer Lipschultz Precision Immunology Institute and The Tisch Cancer Institute at Mount Sinai.

这项合作涉及来自马克和詹妮弗·利普舒尔茨精密免疫学研究所以及西奈山蒂希癌症研究所的专家。

It is expected to provide deeper insights into the mechanisms of action of CAPTN-3, supporting its transition towards clinical trials. Multi-specific engagers have recently attracted increasing attention in oncology research, and this study will contribute to advancing CAPTN-3 development for future human trials..

预计它将为CAPTN-3的作用机制提供更深入的见解，支持其向临床试验的过渡。多特异性参与者最近在肿瘤学研究中引起了越来越多的关注，这项研究将有助于推动CAPTN-3在未来人体试验中的发展。。

Source: globenewswire.com

资料来源：globenewswire.com